Wide Ranks

APLS

Apellis Pharmaceuticals, Inc.

34.14

Top Statistics
Market Cap 4 B Forward PE -39.74 Revenue Growth 78.30 %
Current Ratio 4.36 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -34.97 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -19.47 Enterprise / Revenue 6.03 Price To Sales Trailing12 Months 5.94
Profitability
Profit Margins -34.97 % Operating Margins -24.02 %
Balance Sheet
Total Cash 403 M Total Cash Per Share 3.25 Total Debt 470 M
Total Debt To Equity 198.40 Current Ratio 4.36 Book Value Per Share 1.94
All Measures
Short Ratio 727.00 % Message Board Id finmb_106524288 Shares Short Prior Month 21 M
Return On Equity -1.07 City Waltham Uuid 0d6245e8-6d8f-3e7c-9153-78020c0f85eb
Previous Close 32.63 First Trade Date Epoch Utc 1 B Book Value 1.94
Beta 0.8670 Total Debt 470 M Volume 1 M
Price To Book 17.57 Fifty Two Week Low 24.34 Total Cash Per Share 3.25
Total Revenue 715 M Shares Short Previous Month Date 1 B Target Median Price 46.00
Audit Risk 2 Max Age 86400 Recommendation Mean 1.82
Sand P52 Week Change 0.3133 Operating Margins -24.02 % Target Mean Price 45.75
Net Income To Common -250100992 Short Percent Of Float 0.2552 Implied Shares Outstanding 124 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 5 M
Average Volume10days 5 M Total Cash 403 M Next Fiscal Year End 1 B
Revenue Per Share 5.81 Held Percent Insiders 0.1398 Ebitda Margins -30.97 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 32.63 Target Low Price 24.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 28.74 Open 33.09
Free Cashflow -140212000 State MA Dividend Yield 0.00 %
Return On Assets -0.1623 Time Zone Short Name EST Board Risk 5
Trailing Eps -2.03 Day Low 32.77 Address1 100 Fifth Avenue
Shares Outstanding 124 M Compensation Risk 7 Price Hint 2
Target High Price 78.00 Website https://www.apellis.com 52 Week Change -0.3663
Average Volume 3 M Forward Eps -0.8400 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 359.50 % Is_sp_500 False
Regular Market Day High 34.40 Profit Margins -34.97 % Debt To Equity 198.40
Fifty Two Week High 73.80 Day High 34.40 Shares Short 23 M
Regular Market Open 33.09 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 6.03 Revenue Growth 78.30 % Shares Percent Shares Out 0.1864
Operating Cashflow -205100992 Currency USD Time Zone Full Name America/New_York
Market Cap 4 B Is_nasdaq_100 False Zip 02451
Quote Type EQUITY Industry Biotechnology Long Name Apellis Pharmaceuticals, Inc.
Overall Risk 6 Regular Market Day Low 32.77 Held Percent Institutions 0.9876
Current Price 34.14 Enterprise To Ebitda -19.47 Financial Currency USD
Current Ratio 4.36 Gross Margins 41.66 % Industry Disp Biotechnology
Number Of Analyst Opinions 20 Country United States Float Shares 84 M
Two Hundred Day Average 41.64 Governance Epoch Date 1 B Enterprise Value 4 B
Price To Sales Trailing12 Months 5.94 Forward PE -39.74 Regular Market Volume 1 M
Ebitda -221507008 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.

It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development.

It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases.

The company was incorporated in 2009 and is based in Waltham, Massachusetts.